Skip to main content
. 2024 Nov 19;12(5):qfae078. doi: 10.1093/sexmed/qfae078

Figure 2.

Figure 2

(a) FSFI total score divided by menopausal status, history of breast cancer and use of MHT postoperatively. FSFI,  female sexual function index; MHT, = menopausal hormone therapy, *P < .05-.01, **P < .01-.001. (b) Proportion of women with female sexual dysfunction at baseline and 1-year divided by menopausal status, history of breast cancer and use of MHT postoperatively. FSD, female sexual dysfunction; MHT, menopausal hormone therapy, *P < .05-.01, **P < .01-.001.